Objective: Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. So, the objective of this study was to assess the cost-effectiveness of Durvalumab as consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC.

Methods: PubMed, Scopus, Embase, Cochrane, and EconLit databases were searched till December 2021 to identify all the studies assessing economic evaluation of Durvalumab in patients with unresectable stage III NSCLC who had not progressed after definitive chemoradiotherapy. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. By taking into account purchasing power parity incremental cost-effectiveness ratio (ICER) data were converted to 2022 US dollars ($).

Results: A total of six studies were found to be eligible for inclusion. The majority of studies were conducted in US (n = 3), while the other three studies were conducted in UK, Italy, and Switzerland. Healthcare payers’ perspective was the most common study perspective among the included studies and time horizon varied from 5 years to lifetime. Only one study met the CHEERS reporting standards. Three included studies used the Markov model, while two studies employed the semi-Markov model. The ICER of durvalumab consolidation therapy after unresectable stage III NSCLC in US was found to be in the range of $59,850 to $145,543 per QALY. Likewise, ICER of durvalumab in European countries was found to be in the range of $62,021 to $76,068 per QALY. Durvalumab was found to be cost-effective among all the included studies except one study (cost-effective after 30% discount) as the ICER was below the implemented country-specific willingness-to-pay thresholds.

Conclusion: Durvalumab consolidation therapy was found to be cost-effective versus no consolidation therapy after chemoradiotherapy in patients with stage-III NSCLC.